Metabolic medicines
Pemvidutide
A GLP-1/glucagon candidate with encouraging liver-disease findings, but distinct inflammation and fibrosis results.
Phase 2 human liver trials; phase 3 development
Practical use
Reviewed practical notes
- Separate the endpoints
- Check whether a claim concerns liver fat, MASH resolution or fibrosis.
- Use the right denominator
- A relative liver-fat percentage is not whole-body weight loss.
- Keep development visible
- A phase 3 enrollment page describes research, not routine treatment authorization.
Overview
Pemvidutide activates GLP-1 and glucagon receptors. It is being investigated for metabolic disease, including metabolic dysfunction-associated steatohepatitis (MASH). Liver fat, inflammatory disease activity and fibrosis are different outcomes and should not be collapsed into a claim of liver healing.
Risks and limitations
Adverse events were more common with active treatment than placebo in the cited MASH trial. Limited study duration leaves uncertainty about long-term safety and clinical outcomes such as liver failure. Trial participants received structured medical assessment.
How to read this
Altimmune lists an active phase 3 PERFORMA program. Development activity does not establish approval. The phase 2 findings support further research while preserving the distinction between the endpoint that improved and the one that did not.
Research explained
IMPACT phase 2b biopsy trial
Who was studied
212 adults with biopsy-confirmed MASH and stage F2–F3 fibrosis; a prespecified assessment at 24 weeks within a longer study.
What was found
MASH resolution without worsening fibrosis occurred in 58% and 52% of active groups versus 20% with placebo. Fibrosis improvement without worsening MASH was not statistically significant.
What it cannot establish
Disease-resolution and fibrosis endpoints are different. A favorable result for one cannot be presented as proof of success for both or fewer future liver complications.
Read the original studyShort-term liver-fat trial
Who was studied
94 adults with metabolic dysfunction-associated steatotic liver disease, studied for 12 weeks.
What was found
MRI-measured liver fat fell more in active groups than with placebo.
What it cannot establish
Relative reduction in liver fat is not percentage loss of total body fat and does not itself establish fibrosis reversal.
Read the original studyA biopsy endpoint still needs longer follow-up
A change in MASH activity at a scheduled biopsy is informative. It remains separate from preventing cirrhosis, transplantation or death, which require studies designed to measure those outcomes.
Supporting sourceSources
Altimmune clinical-trial status
Sources checked 2026-10-01.
General education; not a personal treatment plan.